Lucid Diagnostics Inc (NASDAQ:LUCD) price on Friday, July 25, rose 0.91% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.11.
A look at the stock’s price movement, the close in the last trading session was $1.1, moving within a range at $1.075 and $1.11. The beta value (5-Year monthly) was 1.231. Turning to its 52-week performance, $1.80 and $0.72 were the 52-week high and 52-week low respectively. Overall, LUCD moved -4.31% over the past month.
Lucid Diagnostics Inc’s market cap currently stands at around $120.09 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Jun-20.
Analysts have a consensus estimate of 1.15M for the company’s revenue for the quarter, with a low and high estimate of 900k and 1.45M respectively. The average forecast suggests up to a 17.33% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 6.38M, representing a 46.76% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LUCD is a 100% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend LUCD as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LUCD’s current price about -0.40% and -9.41% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 44.54, while 7-day volatility ratio is 4.13% and 6.56% in the 30-day chart. Further, Lucid Diagnostics Inc (LUCD) has a beta value of 1.22. Analysts have given the company’s stock an average 52-week price target of $2, forecast between a low of $2 and high of $2. Looking at the price targets, the low is -80.18% off current price level while to achieve the yearly target high, price needs to move -80.18%. Nonetheless, investors will most likely welcome a -80.18% jump to $2 which is the analysts’ median price.
If we refocus on Lucid Diagnostics Inc (NASDAQ:LUCD), historical trading data shows that trading volumes averaged 0.87 over the past 10 days and 1.22 million over the past 3 months. The company’s latest data on shares outstanding shows there are 84.37 million shares.
The 62.71% of Lucid Diagnostics Inc’s shares are in the hands of company insiders while institutional holders own 9.92% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.79 million on 2025-07-15, giving us a short ratio of 3.08. The data shows that as of 2025-07-15 short interest in Lucid Diagnostics Inc (LUCD) stood at 669.0 of shares outstanding, with shares short rising to 1.66 million registered in 2025-06-13. Current price change has pushed the stock 29.07% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LUCD stock continues to rise going into the next quarter.
